Abstract 6188: Decoding the archetypes and ecotypes of triple-negative breast cancer in responses to chemotherapy

作者：Yun Yan, Yiyun Lin, Tapsi Kumar, Shanshan Bai, Aatish Thennavan, Jianzhuo Li, Tuan M. Tran, Min Hu, Mitchell Rao, Anna Casasent, Elizabeth E. Ravenberg, Gaiane M. Rauch, Alyson R. Clayborn, Debu Tripathy, A.M. Thompson, Bora Lim, L. Huo, L. Huo, SL Moulder, Clinton Yam, Nicholas E. Navin · 发表于：Cancer Research · 年份：2026 · DOI：10.1158/1538-7445.am2026-6188 · 研究领域：Single-cell and spatial transcriptomics、Cancer Immunotherapy and Biomarkers、Ferroptosis and cancer prognosis

Abstract Triple-negative Breast Cancer (TNBC) is an aggressive subtype of breast cancer. The pillar of treatment is chemotherapy, but only half of the patients have a complete response and good survival. To resolve inter- and intra-tumoral heterogeneity and determine their clinical associations, we performed single-cell RNA-sequencing and spatial transcriptomics experiments (including Xenium, Visium HD, and Visium) on treatment-naïve samples of TNBC patients in the ARTEMIS clinical trial. We find that TNBC is classified into 4 major archetypes at patient level: luminal secretory-like, basal-like, interferon responsive, and androgen receptor-enriched. At cell level, cancer cells exhibited intratumoral heterogeneity in 13 gene expression metaprograms. The TNBC tumor microenvironment (TME) consisted of 49 distinct immune and stromal cell states, many of which were reprogrammed relative to normal breast tissues from disease-free women. We further identified 8 ecotypes of cancer cells and TME cell states that co-occurred among patients and were associated with specific archetypes and chemotherapy response groups. Using the Xenium data, we identified 10 distinct spatial niches based on the co-localization of cancer and TME cells, including the tertiary lymphoid structure (TLS) niche, the immune-‘hot’ niche enriched for interferon signaling, and the EMT-associated niche characterized by the angiogenic and ECM-remodeling macrophages together with the hypoxic, EMT-related cancer cells...